Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Immunomodulatory drug

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44356   clinical trials with a EudraCT protocol, of which   7382   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    129 result(s) found for: Immunomodulatory drug. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2010-019173-16 Sponsor Protocol Number: MM5 Start Date*: 2010-07-08
    Sponsor Name:University Hospital Heidelberg
    Full Title: Randomised phase III trial for previously untreated multiple myeloma to evaluate two regimens of bortezomib based induction therapy and lenalidomide consolidation followed by lenalidomide maintenan...
    Medical condition: multiple myeloma (symptomatic, newly diagnosed)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004846-31 Sponsor Protocol Number: 386022010017 Start Date*: 2017-12-14
    Sponsor Name:University medical centre Maribor
    Full Title: Impact of vitamin D supplementation in patients with multiple sclerosis
    Medical condition: Relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10064137 Progression of multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004469-32 Sponsor Protocol Number: CC-5013-CLL-001 Start Date*: 2007-02-23
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 1/2, MULTI-CENTER,OPEN LABEL STUDY OF THE SAFETY AND EFFICACY OF A STEPWISE DOSE-ESCALATION SCHEDULE OF LENALIDOMIDE MONOTHERAPY IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL CHRONIC LYMP...
    Medical condition: For the treatment of relapsed or refractory B-CLL.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003946 B-Lymphocytic, CLL (Kiel Classification) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002497-27 Sponsor Protocol Number: KFJ-2020-01_IMUNOR Start Date*: 2020-10-27
    Sponsor Name:Thomayerova nemocnice
    Full Title: A randomized, open-label, phase IV monocentric study evaluating the clinical effect of oral immunomodulatory therapy with IMUNOR® in patients with moderate COVID-19 disease
    Medical condition: Patients with COVID -19 disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001511-73 Sponsor Protocol Number: WA40404 Start Date*: 2019-12-23
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
    Medical condition:
    Disease:
    Population Age: Gender:
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) PT (Trial now transitioned) IE (Completed) DE (Completed) BG (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) HU (Completed) HR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001381-38 Sponsor Protocol Number: 1 Start Date*: 2021-08-30
    Sponsor Name:Plastikkirurgisk og brystkirurgisk afdeling, Region Sjælland
    Full Title: Topical use of tranexamic acid for optimisation of wound healing in a novel, acute wound model
    Medical condition: Immunomodulation of postoperative inflammatory reactions and thereby reduction of wound fluid production and improved healing by topical administration of tranexamic acid.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10002784 Antifibrinolysis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005592-12 Sponsor Protocol Number: 76873 Start Date*: 2021-08-30
    Sponsor Name:Plastikkirurgisk og brystkirurgisk afdeling, Region Sjælland
    Full Title: The effect of tranexamic acid on seroma formation after mastectomies
    Medical condition: Immunomodulation of postoperative inflammatory reactions and thereby reduction of wound seroma by topical administration of tranexamic acid.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10002784 Antifibrinolysis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002993-19 Sponsor Protocol Number: 54767414MMY3010 Start Date*: 2016-01-11
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory ...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004500-40 Sponsor Protocol Number: CC-5013-NHL-003 Start Date*: 2007-03-28
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE II, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SINGLE-AGENT LENALIDOMIDE (REVLIMID®) IN SUBJECTS WITH RELAPSED OR REFRACTORY AGGRESSIVE NON-HODGKIN’S L...
    Medical condition: Relapsed or refractory aggressive non-Hodgkin's lymphoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029610 Non-Hodgkin's lymphoma unspecified histology aggressive refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-003239-21 Sponsor Protocol Number: CLBH589D2001X Start Date*: 2014-12-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multi-center, expanded treatment protocol of oral panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and relapsed and refractory multiple myeloma
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) NO (Completed) DE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003700-44 Sponsor Protocol Number: BGB-A317-207 Start Date*: 2018-06-21
    Sponsor Name:BeiGene, Ltd. c/o BeiGene USA, Inc.
    Full Title: A Phase 2, Open-Label Study of BGB-A317 in Patients with Relapsed or Refractory Mature T- and NK-cell Neoplasms
    Medical condition: Relapsed or Refractory Mature T- and NK-cell Neoplasms
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025321 Lymphomas non-Hodgkin's T-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-007953-30 Sponsor Protocol Number: cv-07/126 Start Date*: 2008-02-11
    Sponsor Name:Fundación Investigación y Desarrollo en el Área Cardiovascular
    Full Title: Levosimendan como agente inmunomodulador en la insuficiencia cardiaca aguda. Estudio Piloto Levosimendan as an immunomodulatory agent in acute heart failure. Pilot study.
    Medical condition: Analysis of the short-term treatment with levosimendan, a cardiac stimulant drug, of the acute exacerbation of chronic heart failure Estudio del tratamiento a corto plazo con levosimendan, fármac...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002689-19 Sponsor Protocol Number: Allo-Relapse-2011 Start Date*: 2011-11-22
    Sponsor Name: [...]
    1.
    2. Haukeland University Hospital
    Full Title: TREATMENT OF RELAPSED ACUTE LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: DISEASE STABILIZATION THROUGH CHEMOTHERAPY, IMMUNOMODULATORY TREATMENT AND IMMUNOTHERAPY
    Medical condition: Allotransplanted patients with early acute leukemia repse (within 1 year after transplant)
    Disease:
    Population Age: Adults Gender:
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004592-31 Sponsor Protocol Number: APIXABAN Start Date*: 2018-06-22
    Sponsor Name:Health Research Institute Hospital La Fe
    Full Title: Venous Thromboembolism Prophylaxis with Apixaban in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma Receiving Induction Therapy with an Immunomodulatory-Based Regimen
    Medical condition: Venous Thromboembolism (VTE) prophylaxis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001515-20 Sponsor Protocol Number: 12971/16 Start Date*: 2016-10-20
    Sponsor Name:UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
    Full Title: EFFECT OF TERIFLUNOMIDE ON T CELL SUBPOPULATIONS IN PERIPHERAL BLOOD FROM RRMS PATIENTS
    Medical condition: RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003951-44 Sponsor Protocol Number: ΕΑΕ-2017/ΜΜ01 Start Date*: 2017-12-15
    Sponsor Name:Hellenic Society of Hematology
    Full Title: A Prospective, Multicenter, Non-comparative, Open-label, Phase II Study to Evaluate the Effects of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and /or Refractory Multiple M...
    Medical condition: Relapsed and /or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-001236-10 Sponsor Protocol Number: COVID-19 Start Date*: 2020-03-31
    Sponsor Name:Amsterdam UMC
    Full Title: COUNTER-COVID - Oral imatinib to prevent pulmonary vascular leak in Covid19 – a randomized, double --blind, placebo controlled, clinical trial in patients with severe Covid19 disease’
    Medical condition: Covid19 is characterized by hypoxemic respiratory failure, caused by extensive vascular leak and pulmonary edema early in the course of disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004532-10 Sponsor Protocol Number: POI-1 Start Date*: 2018-05-23
    Sponsor Name:Karolinska University Hospital
    Full Title: Effects of immunomodulatory therapy on gonadal function in women with autoimmune premature ovarian insufficiency
    Medical condition: Autoimmune premature ovarian insufficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10052660 Hypergonadotropic hypogonadism LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing) NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003086-40 Sponsor Protocol Number: PIX001 Start Date*: 2008-04-08
    Sponsor Name:Fondation Charcot Stichting
    Full Title: A Phase I/II Study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS)
    Medical condition: aggressive relapsing remitting (RR) or secondary progressive (SP) multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003587-39 Sponsor Protocol Number: COMBAT-MS Start Date*: 2017-05-22
    Sponsor Name:Karolinska Institutet
    Full Title: COMBAT-MS (COMparison Between All immunoTherapies for Multiple Sclerosis) A prospective long-term cohort study of safety, efficacy and patient’s satisfaction of MS disease modulatory treatments in...
    Medical condition: Relapsing-remitting multiple sclerosis (RRMS) that has started on their first or second immunomodulatory drug at the earliest 2011-01-01 and at the latest 2018-06-30. The clinical course and respon...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Aug 20 20:35:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA